






Tamoxifen-rat-HTPBTK-ADMET, RMSLE=0.709 0.05 -0.03 -Concentration (mg/L) factor(Dose) 0.6 factor(Route) – iv 10⁻² 0.005 -0.04 0.02 0.06 0.08 Time (Days)



















































Benzophenone-rat-HTPBTK-ADMET, RMSLE=0.46 1 factor(Dose) 1.88 2.46 Concentration (mg/L) 2.51 3.82 3.84 7.68 10⁻¹ -7.78 factor(Route) iv · oral 10⁻² 0.25 0.50 0.75 0.00 1.00 Time (Days)







Benzophenone-rat-In Vivo Fits, RMSLE=0.321 1 factor(Dose) 1.88 2.46 Concentration (mg/L) 2.51 3.82 3.84 7.68 7.78 10⁻¹ factor(Route) ίV oral 10⁻² -0.25 0.50 0.75 0.00 1.00 Time (Days)











Simazine-rat-In Vivo Fits, RMSLE=0.325 10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 10⁻² factor(Route) iv · oral 10⁻³ -0.05 0.10 0.15 0.00 Time (Days)

















2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-InVitro, RMSLE=1.56




2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-ADMET, RMSLE=1.13




2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-Dawson, RMSLE=1.41




2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-Pradeep, RMSLE=1.52





2-Hydroxy-4-methoxybenzophenone-rat-HTPBTK-Ensemble, RMSLE=1.23





2-Hydroxy-4-methoxybenzophenone-rat-In Vivo Fits, RMSLE=0.426 10² -




















































Bosentan-rat-In Vivo Fits, RMSLE=0.321 1 factor(Dose) Concentration (mg/L) 10 factor(Route) iv · oral 10⁻² -10⁻³ -0.25 0.50 0.75 0.00 1.00 Time (Days)


































































































Propamocarb hydrochloride-rat-HTPBTK-InVitro, RMSLE=2.08 1 -10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.04 0.08 0.00 0.06 Time (Days)


Propamocarb hydrochloride-rat-HTPBTK-ADMET, RMSLE=1.81 10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.04 0.00 0.06 0.08 Time (Days)





Propamocarb hydrochloride-rat-HTPBTK-Ensemble, RMSLE=1.82 10⁻¹ factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 10⁻³ -10⁻⁴ -0.02 0.04 0.00 0.06 0.08 Time (Days)



















S-Bioallethrin-rat-In Vivo Fits, RMSLE=0.254 0.03 factor(Route) Concentration (mg/L) • oral 10⁻² factor(Dose) 0.8 0.003 -10⁻³ -0.1 0.2 0.0 0.3 Time (Days)













Potassium perfluorobutanesulfonate-rat-HTPBTK-InVitro, RMSLE=1.24 10² factor(Dose) 10 -Concentration (mg/L) 20 100 factor(Route) 1 -· oral 10⁻¹ -0.5 1.0 1.5 0.0 2.0 Time (Days)

Potassium perfluorobutanesulfonate-rat-HTPBTK-OPERA, RMSLE=1.24 10² factor(Dose) 10 -Concentration (mg/L) 20 100 factor(Route) 1 -





Potassium perfluorobutanesulfonate-rat-HTPBTK-Ensemble, RMSLE=1.24 10² factor(Dose) 10 -Concentration (mg/L) 20 100 factor(Route) 1 -· oral 10⁻¹ -0.5 1.0 1.5 0.0 2.0 Time (Days)


Potassium perfluorobutanesulfonate-rat-In Vivo Fits, RMSLE=0.496 10² factor(Dose) 10 -Concentration (mg/L) 20 100 factor(Route) · oral 10⁻¹ -0.5 1.0 2.0 0.0 1.5 Time (Days)





Perfluorohexanoic acid-rat-HTPBTK-Ensemble, RMSLE=1.46 10² factor(Dose) 10 -Concentration (mg/L) 40 80 160 factor(Route) · oral 10⁻¹ -0.50 0.00 0.25 0.75 1.00 Time (Days)






































Potassium perfluorohexanesulfonate-rat-HTPBTK-InVitro, RMSLE=0.705 10² factor(Dose) 10 -Concentration (mg/L) 16 32 factor(Route) oral 10⁻¹ -0 10 20 40 30 50 Time (Days)


Potassium perfluorohexanesulfonate-rat-HTPBTK-Ensemble, RMSLE=0.8 10² factor(Dose) 10 -Concentration (mg/L) 16 32 factor(Route) 1 -· oral 10⁻¹ -0 10 20 40 30 50 Time (Days)


Potassium perfluorohexanesulfonate-rat-In Vivo Fits, RMSLE=0.611 10² factor(Dose) 10 -Concentration (mg/L) 16 32 factor(Route) 1 -· oral 10⁻¹ -0 10 20 40 30 50 Time (Days)



































Permethrin-rat-HTPBTK-ADMET, RMSLE=1.17 10⁻¹ -0.03 factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 0.003 -0.5 0.0 2.0 1.0 1.5 Time (Days)


Permethrin-rat-HTPBTK-Dawson, RMSLE=0.968 10⁻¹ -0.03 factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 0.003 -0.5 0.0 2.0 1.0 1.5 Time (Days)





Permethrin-rat-In Vivo Fits, RMSLE=0.296 10⁻¹ -0.03 factor(Dose) Concentration (mg/L) 10⁻² factor(Route) iv · oral 0.003 -0.5 0.0 1.0 2.0 1.5 Time (Days)


























Midazolam-human-HTPBTK-Dawson, RMSLE=0.222 0.3 -Concentration (mg/L) factor(Dose) 0.2 factor(Route) ⊢ iv 10⁻¹ -0.05 -0.01 0.02 0.03 0.04 0.00 Time (Days)


Midazolam-rat-HTPBTK-Ensemble, RMSLE=0.544 0.3 -10⁻¹ -Concentration (mg/L) factor(Route) - oral factor(Dose) 21.6 0.03 -10⁻² 0.10 0.00 0.05 0.15 Time (Days)










Phenazone-rat-HTPBTK-ADMET, RMSLE=0.622 10-Concentration (mg/L) factor(Dose) 15 factor(Route) 10⁻¹ -0.10 0.05 0.15 0.20 0.25 Time (Days)









Phenazone-rat-In Vivo Fits, RMSLE=0.0451 Concentration (mg/L) factor(Dose) 15 0.3 factor(Route) 10⁻¹ -0.10 0.05 0.15 0.20 0.25 Time (Days)







Fenarimol-rat-HTPBTK-Ensemble, RMSLE=0.461 10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 0.03 factor(Route) iv oral 10⁻² -0.003 -0.0 0.1 0.2 0.3 0.4 0.5 Time (Days)

Fenarimol-rat-In Vivo Fits, RMSLE=0.24 10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 0.03 factor(Route) iv oral 10⁻² 0.2 0.4 0.1 0.3 0.0 0.5 Time (Days)


Oxazepam-rat-HTPBTK-InVitro, RMSLE=0.96 10² factor(Dose) 20 Concentration (mg/L) 10 -50 200 400 factor(Route) ίV · oral 1 -0.0 0.3 0.6 0.9 Time (Days)


Oxazepam-rat-HTPBTK-ADMET, RMSLE=0.872 10² factor(Dose) 20 10 -Concentration (mg/L) 50 200 400 factor(Route) · oral 1 -0.0 0.3 0.6 0.9 Time (Days)

Oxazepam-rat-HTPBTK-Dawson, RMSLE=0.894 10² factor(Dose) 10 -20 Concentration (mg/L) 50 200 400 factor(Route) oral 1 -0.0 0.3 0.6 0.9 Time (Days)


Oxazepam-rat-HTPBTK-Pradeep, RMSLE=0.908 10² factor(Dose) 20 Concentration (mg/L) 10 **-**50 200 400 factor(Route) · oral 1 -0.0 0.3 0.6 0.9 Time (Days)


Oxazepam-rat-HTPBTK-Ensemble, RMSLE=0.844 30 -10factor(Dose) 20 Concentration (mg/L) 50 200 400 3 factor(Route) · oral 1 -0.3 -0.0 0.3 0.6 0.9 Time (Days)








Phenacetin-human-HTPBTK-InVitro, RMSLE=0.26 3 factor(Route) oral factor(Dose) Concentration (mg/L) 2.87 3.29 3.33 3.38 3.42 4.24 11.5 0.3 -13.2 13.7 16.9 10⁻¹ -0.10 0.15 0.00 0.05 0.20 Time (Days)




















Phenacetin-human-HTPBTK-Ensemble, RMSLE=0.353 3 factor(Route) oral factor(Dose) Concentration (mg/L) 2.87 3.29 3.33 3.38 3.42 4.24 11.5 0.3 -13.2 13.7 16.9 10⁻¹ -0.10 0.15 0.00 0.05 0.20 Time (Days)





Phenacetin-human-In Vivo Fits, RMSLE=0.202 3 factor(Route) oral factor(Dose) Concentration (mg/L) 2.87 3.29 3.33 3.38 3.42 4.24 11.5 0.3 -13.2 13.7 16.9 10⁻¹ -0.10 0.15 0.00 0.05 0.20 Time (Days)



1-Naphthalenol, 1-(N-methylcarbamate)-rat-HTPBTK-ADMET, RMSLE=1.54 10⁻¹ factor(Dose) Concentration (mg/L) factor(Route) 10⁻² iv · oral 10⁻³ -0.02 0.01 0.03 0.04 Time (Days)







1-Naphthalenol, 1-(N-methylcarbamate)-rat-In Vivo Fits, RMSLE=0.0906 10⁻² factor(Dose) Concentration (mg/L) factor(Route) iv oral 10⁻³ -0.02 0.01 0.03 0.04 Time (Days)

Tolbutamide-rat-HTPBTK-InVitro, RMSLE=0.521 10² factor(Dose) Concentration (mg/L) 10 factor(Route) iv · oral 1 -0.25 0.50 0.75 0.00 1.00 Time (Days)


Tolbutamide-rat-HTPBTK-ADMET, RMSLE=0.536 10² factor(Dose) Concentration (mg/L) 10 factor(Route) iv · oral 1 -0.50 0.75 0.00 0.25 1.00 Time (Days)


Tolbutamide-rat-HTPBTK-Dawson, RMSLE=0.536 10² factor(Dose) Concentration (mg/L) 10 factor(Route) iv · oral 1 -0.50 0.75 0.00 0.25 1.00 Time (Days)


Tolbutamide-rat-HTPBTK-Pradeep, RMSLE=0.536 10² factor(Dose) Concentration (mg/L) 10 factor(Route) iv · oral 1 -0.50 0.75 0.00 0.25 1.00 Time (Days)


Tolbutamide-rat-HTPBTK-Ensemble, RMSLE=0.536 10² factor(Dose) Concentration (mg/L) 10 factor(Route) iv · oral 1 -0.50 0.75 0.00 0.25 1.00 Time (Days)


Tolbutamide-rat-In Vivo Fits, RMSLE=0.0942 10² factor(Dose) Concentration (mg/L) 10 factor(Route) iv oral 1 -0.50 0.75 0.00 0.25 1.00 Time (Days)















Bensulide-rat-In Vivo Fits, RMSLE=0.348 1 factor(Dose) 0.985 Concentration (mg/L) 1.01 1.03 5 5.11 5.17 5.26 factor(Route) 10⁻⁴ -· oral 0.50 0.00 0.25 0.75 1.00 Time (Days)





Dichloromethane-rat-HTPBTK-Ensemble, RMSLE=0.743 10² -10 factor(Route) Concentration (mg/L) oral factor(Dose) 21.2 125 10⁻¹ -0.00 0.05 0.10 0.20 0.15 Time (Days)


























































Pentachlorophenol-rat-In Vivo Fits, RMSLE=0.293 10² factor(Dose) 5 9.5 Concentration (mg/L) 18.8 38 75 150 10 factor(Route) oral 1 -0.0 0.5 1.0 1.5 Time (Days)































2,4-Dichlorophenoxyacetic acid-rat-HTPBTK-InVitro, RMSLE=0.709 10 factor(Dose) 0.202 0.203 0.209 Concentration (mg/L) 1.04 1.5 2 3.56 7 factor(Route) · oral 10⁻³ -0.25 0.50 0.75 0.00 1.00 Time (Days)


2,4-Dichlorophenoxyacetic acid-rat-HTPBTK-ADMET, RMSLE=1.66 10 factor(Dose) 0.202 0.203 0.209 Concentration (mg/L) 1.04 10⁻¹ 1.5 2 3.56 7 factor(Route) · oral 10⁻³ -0.50 0.25 0.75 0.00 1.00 Time (Days)


2,4-Dichlorophenoxyacetic acid-rat-HTPBTK-Pradeep, RMSLE=1.69 10 factor(Dose) 0.202 0.203 0.209 Concentration (mg/L) 1.04 10⁻¹ 1.5 2 3.56 7 factor(Route) · oral 10⁻³ -0.50 0.25 0.75 0.00 1.00 Time (Days)


2,4-Dichlorophenoxyacetic acid-rat-HTPBTK-Ensemble, RMSLE=2.28 10 factor(Dose) 0.202 0.203 0.209 Concentration (mg/L) 1.04 10⁻¹ 1.5 2 3.56 7 factor(Route) · oral 10⁻³ -0.25 0.50 0.75 0.00 1.00 Time (Days)







































tert-Amyl methyl ether-human-HTPBTK-Ensemble, RMSLE=0.306 10⁻² -Concentration (mg/L) factor(Route) oral factor(Dose) 0.0671 0.201 10⁻³ -0.1 0.2 0.4 0.3 0.5 Time (Days)

Ondansetron-rat-HTPBTK-InVitro, RMSLE=0.825 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 1 -20 10⁻¹ -0.05 0.10 0.00 0.15 Time (Days)


Ondansetron-rat-HTPBTK-ADMET, RMSLE=0.655 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 1 -20 10⁻¹ -0.05 0.10 0.00 0.15 Time (Days)





Ondansetron-rat-HTPBTK-Pradeep, RMSLE=0.822 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 20 10⁻¹ -0.05 0.10 0.00 0.15 Time (Days)


Ondansetron-rat-HTPBTK-Ensemble, RMSLE=0.608 10² -10 factor(Route) Concentration (mg/L) · oral factor(Dose) 1 -20 10⁻¹ -0.05 0.10 0.00 0.15 Time (Days)


Ondansetron-rat-In Vivo Fits, RMSLE=0.212 10² factor(Route) 10-Concentration (mg/L) · oral factor(Dose) 20 10⁻¹ -0.10 0.05 0.00 0.15 Time (Days)












Novaluron-rat-HTPBTK-ADMET, RMSLE=1.1 0.3 -10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 0.03 factor(Route) iv · oral 10⁻² -0.003 -2 Ö 3 Time (Days)


Novaluron-rat-HTPBTK-Dawson, RMSLE=1.09 0.3 -10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 0.03 factor(Route) iv · oral 10⁻² -0.003 -2 Ö 3 Time (Days)


Novaluron-rat-HTPBTK-Pradeep, RMSLE=0.949 0.3 -10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 0.03 factor(Route) iv · oral 10⁻² -0.003 -2 Ö 3 Time (Days)


Novaluron-rat-HTPBTK-Ensemble, RMSLE=1.09 0.3 -10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 0.03 factor(Route) iv · oral 10⁻² -0.003 -2 Ö 3 Time (Days)


Novaluron-rat-In Vivo Fits, RMSLE=0.173 0.3 -10⁻¹ factor(Dose) Concentration (mg/L) 0.4 2 0.03 factor(Route) iv oral 10⁻² -0.003 -2 Ó 3 Time (Days)































Oxymetholone-rat-HTPBTK-ADMET, RMSLE=0.952 30 -10factor(Dose) Concentration (mg/L) 20 30 3 **-**120 factor(Route) · oral 1 -0.3 -0.2 0.1 0.5 0.0 0.3 0.4 Time (Days)













Bromochloroacetic acid-rat-HTPBTK-ADMET, RMSLE=1.01 10² -10 factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) oral 10⁻¹ -0.1 0.0 0.2 0.3 Time (Days)


Bromochloroacetic acid-rat-HTPBTK-Pradeep, RMSLE=0.662 10factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) oral 10⁻¹ -0.1 0.0 0.2 0.3 Time (Days)


Bromochloroacetic acid-rat-HTPBTK-Ensemble, RMSLE=0.729 10 factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) oral 10⁻¹ -0.1 0.0 0.2 0.3 Time (Days)


Bromochloroacetic acid-rat-In Vivo Fits, RMSLE=0.386 10 factor(Dose) 10 Concentration (mg/L) 40 80 100 factor(Route) · oral 10⁻¹ -0.1 0.0 0.2 0.3 Time (Days)













Dibromoacetic acid-rat-HTPBTK-ADMET, RMSLE=0.803 10² factor(Dose) 10 10 -25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 oral 10⁻¹ -0.0 0.1 0.2 0.3 Time (Days)


Dibromoacetic acid-rat-HTPBTK-Pradeep, RMSLE=0.587 10² factor(Dose) 10 10-25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 oral 10⁻¹ -0.1 0.2 0.0 0.3 Time (Days)


Dibromoacetic acid-rat-HTPBTK-Ensemble, RMSLE=0.733 10² factor(Dose) 10 10-25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 oral 10⁻¹ -0.1 0.2 0.0 0.3 Time (Days)


Dibromoacetic acid-rat-In Vivo Fits, RMSLE=0.336 10² factor(Dose) 10 10-25 Concentration (mg/L) 40 50 100 110 125 factor(Route) 1 oral 10⁻¹ -0.0 0.1 0.2 0.3 Time (Days)






























Dichloroacetic acid-rat-HTPBTK-ADMET, RMSLE=0.742 10² factor(Route) 10 -Concentration (mg/L) · oral factor(Dose) 10 40 60 100 1 -10⁻¹ 0.0 0.1 0.2 0.3 Time (Days)






Dichloroacetic acid-rat-In Vivo Fits, RMSLE=0.375 30 -10factor(Route) Concentration (mg/L) · oral 3 factor(Dose) 10 40 60 1 -100 0.3 -0.1 0.2 0.0 0.3 Time (Days)








 $4-Methylimidazole-rat-HTPBTK-Pradeep,\ RMSLE=0.6$ 30 -10 factor(Dose) Concentration (mg/L) 10 50 100 3 factor(Route) · oral 1 -0.3 -0.50 0.75 0.00 0.25 1.00 1.25 Time (Days)



 $4-Methylimidazole-rat-HTPBTK-Ensemble,\ RMSLE=0.596$ 30 -10 factor(Dose) Concentration (mg/L) 10 50 100 3 factor(Route) · oral 1 -0.3 -0.50 0.75 0.00 0.25 1.00 1.25 Time (Days)










Anthraquinone-rat-HTPBTK-OPERA, RMSLE=1.16 10 factor(Dose) 2 Concentration (mg/L) 40 100 400 factor(Route) · oral 10⁻¹ -0.25 0.50 0.75 0.00 1.00 Time (Days)

Anthraquinone-rat-HTPBTK-Ensemble, RMSLE=1.13 10 factor(Dose) 2 Concentration (mg/L) 40 100 400 factor(Route) · oral 10⁻¹ -0.25 0.50 0.75 0.00 1.00 Time (Days)







Isoeugenol-rat-HTPBTK-Dawson, RMSLE=0.793 10 factor(Dose) Concentration (mg/L) 17 70 140 factor(Route) · oral 10⁻¹ -0.3 0.0 0.1 0.2 0.4 Time (Days)





Isoeugenol-rat-HTPBTK-Ensemble, RMSLE=0.63 10 factor(Dose) Concentration (mg/L) 17 70 140 factor(Route) · oral 10⁻¹ -0.3 0.0 0.1 0.2 0.4 Time (Days)


Isoeugenol-rat-In Vivo Fits, RMSLE=0.36 10 factor(Dose) Concentration (mg/L) 17 70 140 factor(Route) · oral 10⁻¹ -0.0 0.1 0.2 0.3 0.4 Time (Days)






























Diltiazem-rat-In Vivo Fits, RMSLE=0.439 10factor(Route) Concentration (mg/L) · oral factor(Dose) 20 10⁻¹ -0.2 0.0 0.1 0.3 0.4 Time (Days)




 $Bis (2-chloroethoxy) methane-rat-HTPBTK-Ensemble,\ RMSLE=0.556$ 10 -1 -Concentration (mg/L) factor(Dose) 20 40 factor(Route) 10⁻² -0.2 0.3 0.0 0.1 0.4 Time (Days)














Thiodiglycolic acid-rat-HTPBTK-OPERA, RMSLE=1.03 30 -10-Concentration (mg/L) factor(Dose) 20 3 factor(Route) iv iv 1 -0.3 -0.0 0.1 0.2 0.3 0.4 Time (Days)


















Oxoacetic acid--water (1/1)-rat-HTPBTK-OPERA, RMSLE=0.706 10² -30 -Concentration (mg/L) factor(Dose) 50 factor(Route) iv 10 -3 -0.005 0.010 0.015 0.020 Time (Days)

Oxoacetic acid--water (1/1)-rat-HTPBTK-Ensemble, RMSLE=0.706 10² -30 -Concentration (mg/L) factor(Dose) 50 factor(Route) iv 10 -3 -0.005 0.010 0.015 0.020 Time (Days)



Bromodichloromethane-rat-HTPBTK-OPERA, RMSLE=1.13 10 factor(Dose) 1 -9.34 23.5 Concentration (mg/L) 24 47.1 47.3 87.8 95.7 factor(Route) · oral 10⁻² -0.50 0.25 0.75 0.00 1.00 Time (Days)

Bromodichloromethane-rat-HTPBTK-Ensemble, RMSLE=1.13 10 factor(Dose) 1 -9.34 23.5 Concentration (mg/L) 24 47.1 47.3 87.8 95.7 factor(Route) · oral 10⁻² -0.50 0.25 0.75 0.00 1.00 Time (Days)

